secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001558370-25-003587
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics reports FY2024 net loss $13M, cash $22.8M; APR-1051 data H2 2025
--------------------------------------------------------------------------------

- Net loss of $2.9M (Q4) and $13.0M (FY2024); cash $22.8M, sufficient into Q1 2026.
- ACESOT-1051 trial of WEE1 inhibitor APR-1051 enrolling Cohort 5 (70 mg); open-label data expected H2 2025.
- ABOYA-119 trial of ATR inhibitor ATRN-119 evaluating BID dosing at Dose Level 7; dose escalation completion H2 2025.
- Employment agreement amended for officer John P. Hamill: severance extended to 12 months (18 months post-change-of-control).
- R&D expense increased to $9.4M for FY2024 from $7.6M, driven by trial costs and personnel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837025003587/0001558370-25-003587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837025003587/apre-20250325x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer